Company / Cost of Revenue
Cardiff Oncology, Inc. Cost of Revenue History
FY2016-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
-
FY2019
5-year range
-
FY2016-FY2019
Trend
-100.0%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $2M to $0 over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2019, cost of revenue decreased 100.0% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | $0 | -100.0% |
| FY2018 | $1.8M | +4.7% |
| FY2017 | $1.7M | +11107.3% |
| FY2016 | $15.4K | -97.5% |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026